- Prof. Chunxia Su
- School of Medicine, Tongji University; Deputy Director, Medical Oncology Department, Shanghai Pulmonary Hospital, Shanghai, China.
Website | E-mail
- Prof. Chengzhi Zhou
- State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Website | E-mail
Special Issue Introduction
Lung cancer is the leading cause of cancer death worldwide. Targeted therapy and immunotherapy have dramatically changed the treatment landscape and prolonged the survival of patients. Nevertheless, patients inevitably showed primary resistance or developed acquired resistance, which remains a major unsolved problem.
Understanding deeper resistance mechanisms have become an urgent imperative for current therapies. Mechanisms of resistance could occur after additional genetic alterations of the primary oncogene. The secondary genetic alteration can lead to up-regulation of bypass-signaling pathways, changes in tumor histology, or alterations in drug metabolism. The resistance mechanisms of immunotherapy can be classified into intrinsic mechanisms and extrinsic mechanisms. Intrinsic mechanisms refer to the genetic, transcriptional or functional profile of the tumor cells themselves, while extrinsic mechanisms refer to the tumor microenvironment and factors other than the tumor itself.
Currently, there are many newly developed agents coming into the pipelines of lung cancer treatment to tackle the problems of drug resistance and improve clinical outcomes. With the development of precision medicine, it is pivotal for clinicians to detect drug resistance with re-biopsies techniques, and studying predictive or prognostic biomarkers is also required. These questions should also be well addressed to help us find the resolutions.
This special issue aims to compile a collection of updated research, review and expert opinion articles about the current status and future directions of drug resistance in lung cancer. The resistance mechanisms of current therapies used, strategies to overcome resistance with available or new-generation drugs, platforms and re-biopsy techniques to monitor the existence of drug resistance, and biomarkers for predicting drug resistance will be covered.
● Resistance mechanisms of clinically-used drugs for lung cancer
● Strategies for overcoming resistance and drug development
● Precision oncology methods for monitoring drug resistance
● Predictive or prognostic biomarkers of targeted therapy and immunotherapy for lung cancer treatment
Lung cancer, drug resistance, targeted therapy, immunotherapy, resistance mechanisms, tumor microenvironment
Submission Deadline30 Jun 2023